Teva
The curse of being Israel's most valuable company
Tower's share price has jumped nearly 900% in the past five years, but less than 24 hours after reaching the top, the world's chip stocks plummeted, and Tower's share price tumbled 10.79%
Mega deal: Teva acquires Emalex for approximately $900 million
IATI CEOs Forum meets in Kiryat Gat to discuss multinational industry resilience
Teva honored for gender equality as women reach 43% of senior management in Israel
Teva collaborates on skin disease treatment, releases targets
Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a phase 1b trial for the treatment of vitiligo
Teva seeks startups to help solve global pharmaceutical challenges
Called Teva Rise, it aims to accelerate innovations such as AI, digital health, smart manufacturing and biotech
Placing the focus on the therapist
Teva’s Support the Soul program puts therapists front and center post-October 7
Does a common heart attack pill help everyone? Studies disagree
Two sharply contradictory reports were presented on Saturday at a large cardiology meeting in Madrid.
Irish medical consultants demand state not give sick children Israeli medicine
Teva Pharmaceuticals warned that such a move would “impose a risk on the health and wellbeing” of patients.
Teva’s ‘Support the Soul’ initiative strengthens Israel’s therapists post-October 7
Yarden Abarbanel notes how Teva's trauma-focused program empowers mental health providers nationwide
Former Teva CEO launched bid for World Zionist Congress, warns ‘Israel 4.0 is already here’
The World Zionist Congress, often called the “Jewish parliament,” is the official representative body of the global Jewish people in matters relating to Zionism.
Teva share price struggles to recover following $6 billion market loss
The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 disappointed the market.
Teva falls sharply on disappointing 2025 guidance
"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products," said Teva CEO.
Corruption investigation opened into Teva following employee's complaint
The employee who submitted the complaint requested to be recognized as a whistleblower.